Clinical trials and real-world studies have demonstrated that carfilzomib is effective in improving outcomes for patients with multiple myeloma. Studies such as the ASPIRE trial and ENDEAVOR trial have shown that carfilzomib, particularly in combination with other therapies, can significantly extend progression-free survival and overall survival, offering a promising option for patients with this challenging disease.
